Raymond James analyst Andrew Cooper initiated coverage of Danaher with an Outperform rating and $270 price target. The company has a heavy lean into attractive long-term exposure in bioprocessing and diagnostics businesses, the analyst tells investors in a research note. During “these more challenging times,” the analyst expects quality and market cap size to offer “important relative comfort” in the life science tools sector.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DHR:
- Beckman Coulter Diagnostics, Fujirebio announce new partnership
- Don’t be duped by doomsayers, billionaire Ken Fisher says — this mega-cap-led surge has legs. Here are 3 stocks he’s using to bet on a bounce
- Danaher added to ‘Tactical Outperform’ list at Evercore ISI
- Abcam draws interest from Agilent, Danaher, Bloomberg says
- Abcam an ‘interesting candidate’ for buyout, says RBC Capital